These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
Please note that the physiological activity of the ingredient(s) described herein is supported by the referenced clinical trial reports. Marketers of finished products containing the ingredient(s) described herein are responsible for determining whether claims made for such products are lawful and in compliance with the laws of the country in which they will market the products.


RESEARCH

  • Guo R, PhD et al. Herbal medicines for the treatment of allergic rhinitis: A systematic review.  Ann Allergy Asthma Immunol. 2007 Dec. 99(6): 483-495. Review paper. doi: 10.1016/S1081-1206(10)60375-4 - A review paper with mention of Tinofend extract within. Note that this is not Verdure's paper. 

  • Thawani et al. Short-term effect of Tinospora cordifolia [Tinofend®] in allergic rhinitis. The Antiseptic. 2006 Apr. Vol 3(No 4). 229-232. - A randomized, double-blind, placebo controlled trial in subjects with allergic rhinitis(AR), Tinofend® was shown to significantly improve symptoms commonly associated with AR within 15 days, with further improvements in an additional 15 days. Tinofend was well tolerated and no adverse events were reported.

  • Badar VA et al. Efficacy of Tinospora cordifolia [Tinofend] in allergic rhinitis. J Ethnopharmacol. 2005 Jan 15. Vol 96(Issue 3): 445-449. doi: 10.1016/j.jep.2004.09.034 - A randomized, double-blind, placebo controlled trial in subjects with hay fever (allergic rhinitis), Tinofend® stimulated the activity of white blood cells that regulate the immune response and reduced the number of eosinophils (immune cells which release histamine). It was reported that Tinofend was well tolerated.

 

SUPPORTIVE RESEARCH

  • Chaudhuri PK et al. Nat Prod Com. 2018 Aug. 12(2): 299-308. - A review over the chemistry and pharmacology of Tinospora cordifolia, the plant of which Tinofend® is an extract of. The authors conclude, “The biological study and clinical trials of T. cordifolia are indicative of its safety and potent therapeutic value as a health supplement of commercial importance, as well as a store house for future drug development in critical diseases where modern medicines have limited therapeutic potential.”

  • Castillo et al. Efficacy and safety of Tinospora cordifolia lotion in pediatric patients: A  Single blind, randomized controlled trial. J Pharmacol Pharmacother. 2013. 4(1): 39-46. - A single blind, randomized, controlled pilot study to investigate clinical efficacy of T. cordifolia lotion in 66 patients with scabies in comparison with permethrin lotion. Both lotions significantly reduced the mean global evaluation score after 4 weeks of treatment, and they showed comparable effects; subsequently, T. cordifolia’s incorporation as a therapeutic reagent in scabies infection is highly recommended by the authors.

  • Mishra A et al. Efficacy and safety of Tinospora cordifolia lotion in pediatric patients: A  Single blind, randomized controlled trial. Sci World J. 2013 Aug 31. 2103(Art ID 292934): 8pgs. doi: 10.1155/2013/292934 - This study performed multiple assays to test for antibacterial, antioxidant, and anticancer activity in T. cordifolia, and the results were promising; remarkable potential for all three actions was discovered/reinforced.

  • Saha & Ghosh. Tinospora cordifolia: One plant, many roles. Ancient Sci Life. 2012 Apr-Jun. 31(4): 151-159. doi: 10.4103/0257-7941.107344 - This review goes over the genetic diversity of T. cordifolia and the active constituents of the plant and their role in disease targeting. A myriad of biologically active compounds are contained in the plant, with various roles and actions.

  • Purandare H et al. Immunmodulatory role of Tinospora cordifolia as an adjuvant in surgical  treatment of foot ulcers: A prospective randomized controlled trial. Ind J Med Sci. 2007 Jun. 61(6). 347-355. - A prospective double-blind randomized controlled study lasting 18 months in 50 patients investigated the effects of T. cordifolia as an adjuvant therapy, and it was found that diabetic patients with foot ulcers in the study group showed significantly better final outcome with improvement in wound healing. Also, immunomodulatory effects were indicated due to reduced debridement and improved phagocytosis.

  • Singh RK. Tinospora cordifolia as an adjuvant drug in treatment of patients--case reports. J Vector Borne Dis. 2005 Mar. 42(1): 36-38. - Three separate cases of hyper-reactive malarious splenomegaly who were previously slow responding to the conventional antimalarial drug, chloroquine. An aqueous extract of T. cordifolia (500mg) was added to chloroquine base (300mg) weekly and CQ prophylaxis was observed up to six months. Addition of the extract for the first six weeks showed regression of the spleen, decrease in serum IgM, and increase in Hb and wellbeing (Karnofsky performance scale).

  • Rege et al. Immunotherapy with Tinospora cordifolia: A new lead in the management of  obstructive jaundice. Ind J Gastroenterol. 1993 Jan. 12(1): 5-8. - Thirty patients with malignant obstructive jaundice were randomly divided into two groups; group 1 received conventional management and group 2 received this management plus 16 mg/kg/day of T. cordifolia orally during the period of biliary drainage. Most notably, post-operative survival in groups 1 and 2 was 40% and 92.4% respectively.